ArticleIntegrative cancer therapies
Anti-Hepatocellular Carcinoma Effect of Jianpi Huayu Formula: Revealing the Molecular Mechanisms of the CXCR4 - Smad2/3 Pathway in Regulating Vasculogenic Mimicry Formation and Epithelial-Mesenchymal Transition.
Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LINC01614 favors breast cancer progression through the regulation of miR-217/FN1 and mediation in PI3K/AKT signal pathway.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextHepatocellular carcinoma (HCC) is a malignant tumor with high global incidence and mortality rates. Jianpi Huayu Formula (JPHY) has demonstrated therapeutic potential in HCC, but its underlying mechanisms remain unclear.
objectiveThis study aimed to investigate the anti-HCC effects of JPHY and its molecular mechanisms, focusing on its regulatory roles in vasculogenic mimicry (VM) formation and epithelial-mesenchymal transition (EMT) progression.
methodsSk-Hep-1 cells were treated with 5%, 10%, or 20% JPHY-medicated serum (JPHY-MS). Cell proliferation, migration, VM, and EMT were assessed using CCK-8, wound healing, tube formation, and Western blot assays. Molecular docking was employed to analyze the binding between core components of JPHY and CXCR4. A stable CXCR4-overexpressing cell line was established, and the regulatory effect of CXCR4 on the Smad2/3 pathway was observed following intervention with the Smad2/3-specific inhibitor SB431542. Finally, a retrospective study was conducted using JPHY-MS intervention. In vivo experiments: Mice bearing HCCLM3 xenografts were divided into control, model, low-dose (6.24 g/kg), and high-dose (24.96 g/kg) JPHY groups. Tumor size and body weight were measured every 3 days. The effects of drug intervention on the CXCR4-Smad2/3 pathway, EMT, and VM were examined via immunohistochemistry (IHC), CD31/PAS double staining, and Western blot analysis.
resultsJPHY may impede HCC progression and metastasis through CXCR4 downregulation-mediated suppression of Smad2/3 signaling pathway activation, concomitantly modulating VM formation and EMT processes.
conclusionJPHY suppresses HCC progression by targeting the CXCR4-Smad2/3 pathway, highlighting its potential as a novel HCC therapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.